the label dose, as documented
PT-141 dosage: the approved 1.75 mg dose, timing, and half-life — reported, not prescribed.
What the trials and the FDA label specify, stated as findings. This page recommends no dose for any individual.
Read this first
Plainly: this page reports the doses studied in trials and written on the FDA label. It is not telling you what to take. The approved bremelanotide dose is 1.75 mg injected just under the skin (subcutaneous), as needed, at least 45 minutes before anticipated activity, with hard limits — no more than one dose in 24 hours, and no more than 8 doses a month [6]. That is the regimen used in the RECONNECT trials [3], reported here as a finding. Dosing decisions for any actual person belong with a qualified clinician, not a website. Material sold as a "PT-141 research chemical" is a laboratory form, not the finished approved product, and this site gives no preparation instructions for human use.
The approved 1.75 mg dose, as labeled
The US prescribing information specifies a single 1.75 mg subcutaneous dose, taken as needed at least 45 minutes before anticipated sexual activity, with a ceiling of one dose per 24 hours and no more than 8 doses per month [6]. The approved product is supplied as a prefilled subcutaneous autoinjector, so it is not mixed or reconstituted by the user [6].
The dose wasn't arbitrary. Phase 2 dose-finding in women compared 0.75, 1.25, and 1.75 mg before the 1.75 mg as-needed dose was carried into the pivotal program [research context]. Earlier, separate research used other routes and amounts entirely — intranasal dose-escalation in men reached roughly 7–20 mg, and a Phase 1 metabolic study in women went up to 2.5 mg up to three times daily for 15 days — but those were research protocols, not the approved regimen, and they are reported here only as context [research context][6]. The frequency cap matters for safety: exceeding it is where hyperpigmentation and appetite/weight effects appear in research [6].
How long does PT-141 last?
PT-141 clears the body fairly quickly. After a subcutaneous dose, the terminal half-life is about 2.7 hours (range roughly 1.9–4.0 h) per the label, and the drug reaches peak levels fast — a median Tmax of about 0.5 to 1.0 hour [6]. So measurable drug is largely gone within a single day, which is consistent with the as-needed, take-it-before-activity design rather than a daily medicine [6]. The label's "at least 45 minutes before" timing reflects that fast onset [6].
What is the half-life of PT-141?
The PT-141 half-life is about 2.7 hours (range 1.9–4.0 h) after subcutaneous dosing, per the US prescribing information; early intranasal studies reported a similar 1.85–2.09 h [6]. The supporting pharmacokinetics: volume of distribution ~25.0 L, clearance ~6.5 L/hr, about 21% serum protein binding, with excretion roughly 64.8% renal and 22.8% fecal from a radiolabeled dose [6]. It is broken down by hydrolysis of the cyclic-peptide bonds and ordinary peptidase digestion — the fate of a peptide, not a small-molecule drug [6].